Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

France flag France · Delayed Price · Currency is EUR
0.4650
+0.0040 (0.87%)
Last updated: May 14, 2026, 12:34 PM CET
Market Cap8.35M +24.3%
Revenue (ttm)1.81M +10.7%
Net Income5.48M
EPSn/a
Shares Out18.12M
PE Ratio1.52
Forward PE0.11
Dividendn/a
Ex-Dividend Daten/a
Volume1,460
Average Volume14,336
Open0.4610
Previous Close0.4610
Day's Range0.4420 - 0.4650
52-Week Range0.2800 - 0.9200
Beta-0.32
RSI48.79
Earnings DateMay 14, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 14
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

Financial Statements